Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Alexion Pharmaceuticals)"
Count: 226
Selected: 0
| NCT ID | Title |
|---|
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study) | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT05109390 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults | ||
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | ||
| NCT05047458 | A Study of Single-dose ALXN2050 in Healthy Adults | ||
| NCT05016206 | A Study of the Cardiac Effects of Danicopan in Healthy Adults | ||
| NCT04940559 | Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants | ||
| NCT04935294 | Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction | ||
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | ||
| NCT04889677 | Study of a Single Dose of Danicopan in Healthy Participants | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | ||
| NCT03472885 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT03181633 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | ||
| NCT03108274 | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants | ||
| NCT03053102 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT00401947 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection | ||
| NCT00040144 | Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B | ||
| NCT00034359 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection | ||
| NCT04709094 | A Drug Interaction Study of Danicopan | ||
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | ||
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | ||
| NCT05565092 | Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease | ||
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ||
| NCT05501717 | Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants | ||
| NCT05428696 | Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants | ||
| NCT05396742 | Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers | ||
| NCT05389449 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | ||
| NCT05346354 | Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD | ||
| NCT05319912 | A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT05314231 | Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria | ||
| NCT05307978 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants | ||
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | ||
| NCT05288829 | A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants | ||
| NCT05288816 | A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants | ||
| NCT05288673 | A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants | ||
| NCT05288660 | A Study of a Single Dose of ALXN1210 in Healthy Participants | ||
| NCT05274633 | Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT05259085 | Study of ALXN2050 in Participants With Hepatic Impairment | ||
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants | ||
| NCT05234567 | A Prospective Sub-Study of the Global Hypophosphatasia Registry | ||
| NCT05218096 | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | ||
| NCT05202145 | Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants | ||
| NCT05097989 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN) | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | ||
| NCT05019521 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | ||
| NCT04999020 | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis |
